Dosages form Development Pre formulation Studies Bulk Characterization Part 1

Main ideas / lessons conveyed

• Pre-formulation studies are “learning before doing.” Before developing a dosage form (tablets, capsules, injections, etc.), the drug must be thoroughly characterized:
  • Physico-chemically
  • Biologically
  • Microbiologically
  • Immunologically
• Compatibility must also be assessed between the drug and all planned excipients.

Goal: Use the drug’s properties to design a dosage form that is:

• Stable
• Bioavailable
• Safe
• Likely to perform similarly in in vitro tests and in vivo (clinical) outcomes

Why they matter: Without understanding drug properties, formulation development becomes inefficient—often requiring many redesigns after failures.

Application across development: Pre-formulation is not a one-time activity. It is refined across preclinical and clinical phases, including adjustments for animal-to-human extrapolation, such as:

• selecting solubilizers
• choosing processing conditions
• defining storage conditions

Types of drug entities addressed:

• Drug (active moiety): the direct pharmacologically active molecule.
• Prodrugs: derivatives that must be transformed in vivo to release the active drug
  • Example: erythromycin estolate releasing erythromycin
  • Used to improve stability, solubility, taste, and tolerability

Solid-form / bulk characterization is foundational for predicting solubility, stability, and manufacturability—because performance depends on:

• crystal form (polymorphs)
• hydrates/solvates
• clathrates
• related phase and transition behaviors

---

Methodology / structure of pre-formulation work (detailed bullet points)

1) Identify what must be characterized before dosage-form development

Drug characterization (before formulation):

• Physico-chemical characterization
• Biological characterization
• Microbiological characterization
• Immunological characterization

Compatibility assessment:

• Study the drug in combination with all planned excipients
• Determine whether excipients:
  • maintain stability
  • cause destabilization
  • lead to undesirable changes (e.g., moisture-driven issues or formation of new solid forms)

---

2) Determine how the drug behaves and what design constraints exist

Physical characteristics to understand:

• Solubility
• Particle size
• Surface area
• Moisture absorption tendency
• Stability/destabilization behavior under moisture and environmental conditions

Chemical and kinetic understanding:

• Degradation/destabilization kinetics, including models such as:
  • First-order
  • Second-order
  • Pseudo-first-order

Stability and processing implications:

• If the drug is thermolabile/thermosensitive:
  • avoid high-temperature processing (if needed)
  • propose proper storage conditions
  • ensure drug and ingredients remain stable and bioavailable

---

3) Predict formulation performance and correlate in vitro vs in vivo

Evaluate risks such as:

• Solubilization problems
• In vitro performance that fails to translate into in vivo absorption

Use particle characteristics and formulation choices to support:

• Coherence/correlation between in vitro dissolution and in vivo solubilization
• Reduced risk of poor bioavailability

---

4) Decide dosage form type based on in vitro and in vivo needs

Consider:

• shelf/in vitro behavior vs in vivo behavior
• practical factors:
  • large-scale processing
  • transportation
  • storage

Permeability to influence route/type (example logic):

• If permeability is very poor (e.g., highly hydrophilic drug):
  • oral route may fail due to poor dissolution and absorption
  • consider alternatives such as:
    • injection
    • topical forms (e.g., ointment with hydrophobic base)

---

5) Integrate pre-formulation into the overall drug development pipeline

After the active moiety is obtained:

• Preclinical studies + pre-formulation happen together to select an approach/formulation
• Formulation continues to optimize (not finalized initially)

If preclinical results are positive:

• proceed to clinical trials (volunteers, then phase escalation)

Adjust formulation for interspecies differences:

• drugs may absorb in animals but not in humans
• differences in gastric juice composition and pH may require solubilizers or other changes

After successful clinical phases:

• proceed to large-scale manufacturing
• then launch/marketing

Pre-formulation is described as progressing simultaneously through these stages.

---

Specific characterization studies mentioned

A) Objectives of pre-formulation (explicitly listed)

• Establish physical and chemical properties of the new drug entity
• Determine kinetics / degradation behavior
• Determine excipient compatibility
• Decide processing and storage conditions
• Estimate formulation-related problems and ensure in vitro–in vivo coherence

Ultimately, enable a dosage form that:

• is stable
• is bioavailable
• minimizes side effects
• maximizes delivery to the target area

---

B) Physical characterization (as described)

Bulk properties / particle characteristics

• Shape, size
• Flow properties and bulk properties
• Porosity, density
• Hygroscopicity
• Crystalline polymorphism

Solubility analysis

• pKa determination
• Solubilization behavior
• Aqueous solubility
• pH-dependent solubility
• “Dependent solubility” (as stated)
• Partition coefficient
• Thermal effect
• Common ion effect
• Dissolution studies

Stability analysis

• Solid-state stability
• Solution-state stability
• Drug–excipient compatibility and stability

---

C) Chemical characterization (as described)

Chemical reactions/disruption possibilities include:

• Oxidation
• Photolysis
• Free radical reactions
• Hydrolysis
• Racemization
• Isomerization
• Enzyme decomposition
• Decarboxylation

---

Detailed bulk/solid-state characterization concepts (key concepts emphasized)

• Particle/bulk properties are a first step toward designing a suitable, bioavailable dosage form.

Crystallinity

• Crystal habit and internal structure influence:
  • flowability
  • packing
  • chemical stability

Crystal habit vs internal structure

• Habit = outer appearance
• Internal structure = molecular arrangement in the solid

Crystal vs amorphous

• Crystalline forms are generally more thermodynamically stable.
• Amorphous forms can be formed by:
  • rapid precipitation
  • lyophilization
  • rapid cooling of melts

Phase transitions to watch

• Polymorphic transitions
• Hydration/dehydration
• Solvated/desolvated transitions
• Salt–salt conversions (e.g., chloride salt ↔ bromide salt)

Solvates/hydrates vs non-stoichiometric forms

• Hydrates contain water; hydrates (as stated) refers generally to solvent-including forms
• Stoichiometric solvate: solvent incorporated at specific lattice sites
• Non-stoichiometric adducts: inclusions/clathrates with entrapped solvent

Polymorphism

• Same compound exists in multiple distinct crystalline species (different internal lattices)
• Different forms can have different chemical/physical stability and solubility
• Selecting a polymorph requires knowledge of:
  • stability temperatures
  • solubility of each form
  • risk of conversion during processing (which may reduce solubility)

Toxic/clinical relevance

• Highly crystalline forms may cause irritation (e.g., to mucosal lining)

Analytical methods for solid form characterization

• Microscopy:
  • optical microscopy
  • scanning electron microscopy / transmission electron microscopy (for very small particles)
  • hot-stage microscopy for temperature-dependent transformations
• X-ray diffraction:
  • powder X-ray diffraction
• Spectroscopy and others:
  • NMR (powder sample orientation mentioned)
  • FTIR
• Thermal/thermal-analytical techniques:
  • differential scanning calorimetry (DSC)
  • DTA
  • TGA
  • melting point determination
  • dilatometry and microcalorimetry
• Clathrate identification:
  • via melting behavior (host/guest distinct components)

---

Conclusion / takeaway

• Pre-formulation studies establish the foundation for rational dosage form design by providing sound knowledge of:
  • physical
  • chemical
  • biological properties
• Dosage form selection should be driven by the drug’s properties; poor solubility/permeability may necessitate non-oral routes (e.g., injection).
• Future lectures will cover more aspects of the drug’s physical, chemical, and biological properties.

---

Speakers / sources featured

• No specific named speakers, guests, or sources are mentioned in the subtitles.